Eli Lilly has shared one-year histologic outcomes from a phase 3 study of its interleukin-23p19 antagonist mirikizumab in ...

A US Food and Drug Administration (FDA) panel of experts has voted in support of Stealth BioTherapeutics’ elamipretide for ...

• Mtech Access – Powered by Petauri™ are excited to be returning to ISPOR Europe this November. The team will be joined by ...

Patient Recruitment company, Innovative Trials, appointed new Finance and Business Services Director Innovative Trials have ...

Up to 20% of patients will develop metastatic castration-resistant disease within five to seven years of diagnosis ...

Eli Lilly has partnered with insitro to advance new treatments for metabolic diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD). The new drugs developed under the ...

Astellas Pharma and AviadoBio have entered into an exclusive option and licence agreement worth over $2bn for an ...

See more about this new insights product, Medscape AffinityTM, which offers unparalleled insights into the online behaviour of 13M+ HCPs to help you make fully informed decisions around your brand and ...

Merck & Co – known as MSD outside the US and Canada – has shared positive results from a late-stage study of its anti-PD-1 therapy in head and neck cancer. The phase 3 KEYNOTE-689 trial has been ...

Ipsen’s Iqirvo (elafibranor) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with primary biliary cholangitis (PBC). The oral peroxisome ...

Johnson & Johnson (J&J) has announced results from a real-world study comparing its Erleada (apalutamide) to Pfizer and ...

What clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of ...